DB
IBO

Danske Bank’s Impact BioMedical IBO Stock Holding History

Danske Bank’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
3
– – ﹤0.01% 1151
2025
Q4 		$2 Hold
3
– – ﹤0.01% 1543
2025
Q3 		$2 Hold
3
– – ﹤0.01% 1475
2025
Q2 		$2 Hold
3
– – ﹤0.01% 1504
2025
Q1 		$3 Hold
3
– – ﹤0.01% 1338
2024
Q4 		$4 Hold
3
– – ﹤0.01% 1363
2024
Q3 		$6 Buy
+3
New +$7 ﹤0.01% 1551

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Danske Bank's IBO Position: Q1 2026 in Review

Danske Bank held its Impact BioMedical (IBO) position steady in Q1 2026 at 3 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

Danske Bank first reported a position in IBO in Q3 2024 and has held it in 7 quarters since. The position peaked at $6 in Q3 2024. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Danske Bank held 3 shares of Impact BioMedical worth $2 as of Q1 2026.
  • Danske Bank left its Impact BioMedical share count unchanged in Q1 2026.
  • Impact BioMedical made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1151 holding.
  • Danske Bank first reported a position in Impact BioMedical in Q3 2024 and has held it in 7 quarters since.
  • Danske Bank's Impact BioMedical position peaked at $6 in Q3 2024.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.